Shoddy biopsies deny cancer patients a shot at personalized treatment
Elie Dolgin • January 22, 2016
A huge federal trial of personalized cancer medicine has run into an unexpected roadblock: Many of the tumor samples aren’t robust enough to be put through genetic analysis.
Continue reading at
STAT.
Paul Mischel is championing the importance of odd rings of DNA in tumors — and their promise as targets for cancer therapy.
Edits create cells that don’t trigger an immune response, allowing implant recipient to forego immune-suppressing drugs.